Chemical Decomposition of 5-Aza-2′-deoxycytidine (Decitabine): Kinetic Analyses and Identification of Products by NMR, HPLC, and Mass Spectrometry

被引:75
作者
Rogstad, Daniel K. [1 ]
Herring, Jason L. [1 ]
Theruvathu, Jacob A. [1 ]
Burdzy, Artur [1 ]
Perry, Christopher C. [1 ]
Neidigh, Jonathan W. [1 ]
Sowers, Lawrence C. [1 ]
机构
[1] Loma Linda Univ, Sch Med, Dept Basic Sci, Loma Linda, CA 92350 USA
基金
美国国家卫生研究院;
关键词
DNA METHYLTRANSFERASE; ALPHA ANOMER; PHASE-I; 5-AZACYTIDINE; 5-AZA-2-DEOXYCYTIDINE; CELLS; METHYLATION; INHIBITION; DEMETHYLATION; SPECTROSCOPY;
D O I
10.1021/tx900131u
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The nucleoside analogue 5-aza-2'-deoxycytidine (Decitabine, DAC) is one of several drugs in clinical use that inhibit DNA methyltransferases, leading to a decrease of 5-methylcytosine in newly replicated DNA and subsequent transcriptional activation of genes silenced by cytosine methylation. In addition to methyl transferase inhibition. DAC has demonstrated toxicity and potential mutagenicity, and can induce a DNA-repair response. The mechanisms accounting for these events are not well understood. DAC is chemically unstable in aqueous solutions, but there is little consensus between previous reports as to its half-life and corresponding products of decomposition at physiological temperature and pH, potentially confounding studies on its mechanism of action and long-term use in humans. Here, we have employed a battery of analytical methods to estimate kinetic rates and to characterize DAC decomposition products under conditions of physiological temperature and pH. Our results indicate that DAC decomposes into a plethora of products, formed by hydrolytic opening and deformylation of the triazine ring, in addition to anomerization and possibly other changes in the sugar ring structure. We also discuss the advantages and problems associated with each analytical method used. The results reported here will facilitate ongoing studies and clinical trials aimed at understanding the mechanisms of action, toxicity, and possible mutagenicity of DAC and related analogues.
引用
收藏
页码:1194 / 1204
页数:11
相关论文
共 39 条
[1]   Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors [J].
Appleton, Kim ;
Mackay, Helen J. ;
Judson, Ian ;
Plumb, Jane A. ;
McCormick, Carol ;
Strathdee, Gordon ;
Lee, Chooi ;
Barrett, Sophie ;
Reade, Sarah ;
Jadayel, Dalal ;
Tang, Adrian ;
Bellenger, Katharine ;
Mackay, Lynsay ;
Setanoians, Albert ;
Schaetzlein, Andreas ;
Twelves, Chris ;
Kaye, Stanley B. ;
Brown, Robert .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (29) :4603-4609
[3]  
Bender CM, 1998, CANCER RES, V58, P95
[4]   AN IMPROVED SYNTHESIS OF 2'-DEOXY-5-AZACYTIDINE BY CONDENSATION OF A 9-FLUORENYLMETHOXYCARBONYL-PROTECTED SUGAR ONTO THE SILYLATED BASE [J].
BENHATTAR, J ;
JIRICNY, J .
JOURNAL OF ORGANIC CHEMISTRY, 1986, 51 (16) :3211-3213
[5]  
BOUCHARD J, 1983, MOL PHARMACOL, V24, P109
[6]  
BRAUN S, 1998, 150 MORE BASIC NMR E, P140
[7]   KINETICS OF DEAMINATION OF 5-AZA-2'-DEOXYCYTIDINE AND CYTOSINE-ARABINOSIDE BY HUMAN-LIVER CYTIDINE DEAMINASE AND ITS INHIBITION BY 3-DEAZAURIDINE, THYMIDINE OR URACIL ARABINOSIDE [J].
CHABOT, GG ;
BOUCHARD, J ;
MOMPARLER, RL .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (07) :1327-1328
[8]   5-AZACYTIDINE HYDROLYSIS KINETICS MEASURED BY HIGH-PRESSURE LIQUID-CHROMATOGRAPHY AND C-13-NMR SPECTROSCOPY [J].
CHAN, KK ;
GIANNINI, DD ;
STAROSCIK, JA ;
SADEE, W .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (07) :807-812
[9]   5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation:: mechanistic studies and their implications for cancer therapy [J].
Christman, JK .
ONCOGENE, 2002, 21 (35) :5483-5495
[10]   Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment [J].
Daskalakis, M ;
Nguyen, TT ;
Nguyen, C ;
Guldberg, P ;
Köhler, G ;
Wijermans, P ;
Jones, PA ;
Lübbert, M .
BLOOD, 2002, 100 (08) :2957-2964